There is no established standard for selection of mismatched unrelated donors. Indirect recognition of HLA mismatches can be predicted using the model of "Predicted Indirectly ReCognizable HLA Epitopes" (PIRCHE). We performed a multicenter retrospective study evaluating the impact PIRCHE on outcome after allogeneic stem cell transplantation (allo-HSCT) from single mismatched (HLA 9/10 matched) unrelated donors. The study cohort included 424 adult recipients of HLA 9/10 matched unrelated donor transplants (9/10 MUD), treated for AML or MDS at 6 transplant centers across Germany. Detection of PIRCHE was associated with lower overall survival (OS) (47 vs. 57%, p = 0.04), higher non-relapse mortality (NRM) (32 vs. 20%, p = 0.05), and higher incidence of chronic graft-versus-host disease (GVHD) (49 vs. 31%, p = 0.04) at 2 years. Cumulative incidence of acute GVHD grade 2-4 at 6 months was not significantly different (30 vs. 23%, p = 0.2). OS for 9/10 MUD with no PIRCHE was similar to 10/10 MUD (57 vs. 55%). In multivariate analysis, PIRCHE retained negative impact on OS (RR 1.5, 95% CI 1.0-2.1, p = 0.03) and NRM (RR 1.7, 95% CI 1.0-2.9, p = 0.03). To the best of our knowledge, for the first time, we show the association of PIRCHE and survival outcome after allo-HSCT. The PIRCHE model, if validated in an independent cohort, may allow selection of permissible HLA mismatches that enable improved transplant outcome.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for several hematological disorders. If no matched related donor is available, the probability of finding a fully HLA-matched unrelated donor (MUD) may be as low as 16%, depending on the patient's ethnical background [1] . Donor-recipient HLA mismatching is associated with poorer outcome [2] [3] [4] [5] [6] . Transplant outcome with permissible HLA mismatches such as in HLA-DPB1 or HLA-C*03: 03/03: 04 is similar to that with fully matched unrelated donors [7] [8] [9] [10] [11] .
Direct recognition of HLA-DPB1 mismatches can be predicted using the TCE (T-cell epitope) model, based on which DPB1 mismatches can be categorized as permissive or non-permissive [9, 10] . Direct recognition of HLA mismatches can also be predicted by in silico models; however, none of them has so far predicted clinical outcome [12, 13] . Indirect recognition of HLA mismatches can be predicted using the model of "Predicted Indirectly ReCognizable HLA Epitopes" (PIRCHE). The PIRCHE model is a recently developed computer-based strategy, which classifies HLA-derived epitopes that are potentially presented by patient-donor shared HLA molecules. Accordingly, PIRCHE-I are presented by shared HLA class I and PIRCHE-II by shared HLA class II molecules, independent of the mismatched locus [14] . PIRCHE numbers correlate with incidence of acute graft-versushost disease (GVHD) [15] .
We reasoned that by predicting donor-recipient alloreactivity, the PIRCHE model separates permissible from non-permissible HLA mismatches and would therefore predict outcome after single-mismatched (9/10 MUD) HSCT.
Patients and Methods
A study protocol was written by F.A. and W.B. and amended by the German cooperative transplant study group. Data were collected according to EBMT guidelines and updated as of January 2016. Written informed consent was available from all patients.
The main objective was evaluation of the impact of PIRCHE on outcome of 9/10 MUD HSCT. The primary endpoint was overall survival (OS) at 2 years. Secondary endpoints were cumulative incidence of acute GVHD at 6 months, non-relapse mortality (NRM) at 2 years, and chronic GVHD at 2 years.
Unambiguous allele-level high-resolution HLA-A, -B, -C, -DRB1, and -DQB1 typing was available for all patient-unrelated donor pairs at the time of transplant. Lower level typing was considered sufficient for related donors. Transplants from mismatched related donors and those using umbilical cord blood grafts were excluded from the analysis.
The entire study included 1,997 adult patients: matched related donors = 481, 10/10 MUD = 978, 9/10 MUD = 424, 8/10 MUD = 97, 7/10 MUD = 17. Detailed analyses were performed in the cohort of patients with a 9/10 MUD (n = 424). PIRCHE numbers were computed for 9/10 MUD using a webbased tool provided by PIRCHE AG (www.pirche.org). Accordingly, PIRCHE I and II values were computed for each patient and the sum of PIRCHE I and II was considered as PIRCHE score. Patients with a 9/10 MUD were then divided into 2 groups according to the sum of PIRCHE I + II values (PIRCHE score). Eighty-five patients had a PIRCHE score of 0 (no PIRCHE detected), 339 a PIRCHE score > 0.
Patient characteristics of the 424 patients with 9/10 MUD are summarized in Table 1 . Acute and chronic GVHD were defined according to international consensus criteria [16, 17] . Details of HLA mismatches and their respective PIRCHE numbers are provided as online supplementary Table S1 (for all online suppl. material, see www.karger.com/doi/10.1159/000502389).
Statistical Analysis
Categorical variables were expressed as frequencies, while continuous variables were expressed as medians and ranges. For all analyses, patients still alive were censored at last follow-up. If patients received a second allogeneic transplant, they were considered alive or dead due to relapse or NRM if the event occurred. Missing data were excluded from analysis.
Categorical data were compared by chi-square test or Fisher's exact test. OS was estimated using the method of Kaplan-Meier and compared using the log-rank test. Competing risk analyses were performed with death as competing risk for acute GVHD and chronic GVHD and relapse as competing risk for NRM.
All parameters in patient demographics (Table 1) were included in the univariate analysis. Parameters with p < 0.05 were thereafter entered into a Cox regression model with stepwise backward elimination (Wald). All reported p values are two-sided. Though not significant in univariate analysis, HLA-C allele vs. antigen mismatch and HLA-C*03: 03 vs. 03: 04 mismatch were also included in multivariate analysis models because they were not evenly distributed (Table 1) .
Calculations were performed with IBM SPSS, version 22 (SPSS Inc., Chicago, IL, USA). Competing risks analyses were performed using R (www.r-project.org).
Results

Overall Survival
First, we examined the impact of the PIRCHE score (sum of PIRCHE I and II) on OS of the patient cohort. Kaplan-Meier estimate of 2-year OS was higher for 9/10 MUD with a PIRCHE score = 0 compared to > 0: 57% (95% CI 51-63%) vs. 47% (95% CI 41-53%), p = 0.04 ( Fig. 1 ). OS was similar for 9/10 MUD with a PIRCHE score = 0 and 10/10 MUD (57 vs. 55%). Neither PIRCHE I nor PIRCHE II alone had significant impact on OS (data not shown). Cox regression analysis revealed poorer OS for PIRCHE score > 0 (RR 1.5, 95% CI 1.0-2.1, p = 0.03; Table 2a ).
Relapse and Non-Relapse Mortality
Next, we sought to understand the reason for the difference in OS and therefore analyzed the impact of PIRCHE score on NRM and relapse. Cumulative incidence of NRM at 2 years was lower for 9/10 MUD with PIRCHE score = 0 compared to a PIRCHE score > 0 (20 vs. 32%, p = 0.05; Fig. 2 ). Multivariate Cox regression analysis revealed poorer NRM for PIRCHE score > 0 (RR 1.7, 95% CI 1.0-2.9, p = 0.03; Table 2b ). Cumulative incidence of relapse was similar for 9/10 MUD with PIRCHE score = 0 compared to a PIRCHE score > 0 (22 vs. 23%, p = 0.73). DOI: 10.1159/000502389 
Graft-Versus-Host Disease
Finally, we analyzed the impact of PIRCHE score on acute and chronic GVHD. Cumulative incidence of acute GVHD grade 2-4 at 6 months was not different for 9/10 MUD with PIRCHE score 0 compared to PIRCHE score > 0 (23 vs. 30%, p = 0.2; Fig. 3 ). Cumulative incidence of chronic GVHD at 2 years was lower for 9/10 MUD with PIRCHE score 0 compared to PIRCHE score > 0 (31 vs. 49%, p = 0.04; Fig. 4 ).
Discussion
Single mismatched unrelated donors are one of the most frequently used alternative graft sources for allogeneic stem cell transplantation. However, there is no established standardized system for selection of HLA-mismatched donors. Although associations between specific HLA disparities and outcome have been identified in large cohort studies [18] [19] [20] , these findings are limited to the specific HLA loci and the particular mismatch under investigation. More so, the HLA heterogeneity in ethnically mixed populations like Europeans and the Americans, poses a major barrier to such epidemiologically based strategies [21] .
Our study is based on high-resolution typing for HLA-A, -B, -C, -DRB1, and -DQB1 because this is general practice in the participating centers. Typing for HLA-DPB1 was not routinely performed. The differential impact of single HLA disparities in locus A, B, C, and DRB1 has been and is still an issue of controversy [3, 4, 6] . In our study, HLA-A disparity was associated with higher risk of NRM compared to other HLA mismatches (Table 2a, b) . Transplants with disparities in HLA-DQB1 were associated with better OS than other mismatches, also confirming previous reports [3, 4, 6] . Data are presented as n (%) or median (range). The cohort of 424 patients transplanted from a 9/10 MMUD was stratified according the PIRCHE score = 0 (n = 85) or > 0 (n = 339). For Kaplan-Meier estimates, see text. Our results show that the PIRCHE algorithm enables detection of permissive mismatches in 9/10 MUD HSCT. Such permissive mismatches may include already known alleles such as HLA-C*03: 03 vs. 03: 04 as well as others that have not yet been specifically studied. In our cohort, detection of any PIRCHE (score > 0) was associated with poorer outcome in terms of NRM and OS.
The current PIRCHE model considers all peptides within defined binding values as relevant and scores them equally, irrespective of their positioning in the peptide binding groove of the HLA molecule and polymorphisms that may influence T-cell recognition [21] . A higher PIRCHE score may therefore not necessarily reflect a proportional increase in alloreactivity. This is a possible reason why increasing PIRCHE numbers as continuous variable were not associated with survival outcome (data not shown).
Detection of PIRCHE was associated with a higher cumulative incidence of chronic GVHD but not acute GVHD. This finding is in line with the notion that indirect T-cell recognition, which is believed to involve the naïve rather than memory T cells, may elicit slow rather than early acute alloreactivity [22] . PIRCHE is currently the only existing model that predicts indirect recognition of HLA mismatches. The PIRCHE model has recently been reported to refine the TCE model for selection of permissible HLA-DPB1 epitopes [23] indicating that models predicting direct and indirect recognition of HLA mismatches may be complementary.
To the best of our knowledge, for the first time, we report a clinically relevant impact of this computer-based prediction of indirect T-cell recognition of HLA mismatches on survival outcome after allogeneic HSCT.
Our study is limited by its retrospective character and lack of DPB1 typing. Our results nonetheless indicate that PIRCHE may allow selection of permissible HLA mismatches that would enable improved transplant outcome in terms of reduced NRM and better OS. These results, . 3 . Cumulative incidence of acute GVHD according to PIRCHE score. The cohort of 424 patients transplanted from a 9/10 MMUD was stratified according the PIRCHE score = 0 (n = 85) or > 0 (n = 339). For Kaplan-Meier estimates, see text. Fig. 4 . Cumulative incidence of chronic GVHD according to PIRCHE score. The cohort of 424 patients transplanted from a 9/10 MMUD was stratified according the PIRCHE score = 0 (n = 85) or > 0 (n = 339). For Kaplan-Meier estimates, see text.
Transfus Med Hemother 2019;46:370-375 DOI: 10.1159/000502389 however, need confirmation in another large retrospective or prospective study before PIRCHE can become a new instrument for selection of HLA-mismatched donors.
